Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 24, Issue 4, Pages 543-545Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458517704507
Keywords
Multiple sclerosis; rituximab; monoclonal antibodies; B-lymphocytes; positron emission tomography; magnetic resonance imaging
Categories
Funding
- Bayer Schering Pharma
- Biogen
- Roche
- GlaxoSmithKline
- Merck Serono
- Novartis
- Teva
Ask authors/readers for more resources
Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4weeks after the first administration. The exact mechanisms leading to this rapid effect have not yet been clarified. The aim of this positron emission tomography study was to assess central nervous system penetration as a possible explanation, using zirconium-89-labelled rituximab. No evidence was found for cerebral penetration of [Zr-89]rituximab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available